Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus

Kathleen McElhone, Janice Abbott, Chris Sutton, Montana Mullen, Peter Lanyon, Anisur Rahman, Chee-Seng Yee, Mohammed Akil, Ian N Bruce, Yasmeen Ahmad, Caroline Gordon, Lee-Suan Teh, Kathleen McElhone, Janice Abbott, Chris Sutton, Montana Mullen, Peter Lanyon, Anisur Rahman, Chee-Seng Yee, Mohammed Akil, Ian N Bruce, Yasmeen Ahmad, Caroline Gordon, Lee-Suan Teh

Abstract

Objective: As a health-related quality of life (HRQOL) measure, the LupusQoL is a reliable and valid measure for adults with systemic lupus erythematosus (SLE). This study evaluates the responsiveness and minimal important differences (MIDs) for the 8 LupusQoL domains.

Methods: Patients experiencing a flare were recruited from 9 UK centers. At each of the 10 monthly visits, HRQOL (LupusQoL, Short Form 36 health survey [SF-36]), global rating of change (GRC), and disease activity using the British Isles Lupus Assessment Group 2004 index were assessed. The responsiveness of the LupusQoL and the SF-36 was evaluated primarily when patients reported an improvement or deterioration on the GRC scale and additionally with changes in physician-reported disease activity. MIDs were estimated as mean changes when minimal change was reported on the GRC scale.

Results: A total of 101 patients were recruited. For all LupusQoL domains, mean HRQOL worsened when patients reported deterioration and improved when patients reported an improvement in GRC; SF-36 domains showed comparable responsiveness. Improvement in some domains of the LupusQoL/SF-36 was observed with a decrease in disease activity, but when disease activity worsened, there was no significant change. LupusQoL MID estimates for deterioration ranged from -2.4 to -8.7, and for improvement from 3.5 to 7.3; for the SF-36, the same MID estimates were -2.0 to -11.1 and 2.8 to 10.9, respectively.

Conclusion: All LupusQoL domains are sensitive to change with patient-reported deterioration or improvement in health status. For disease activity, some LupusQoL domains showed responsiveness when there was improvement but none for deterioration. LupusQoL items were derived from SLE patients and provide the advantage of disease-specific domains, important to the patients, not captured by the SF-36.

© 2016, The Authors. Arthritis Care & Research published by Wiley Periodicals, Inc. on behalf of the American College of Rheumatology.

Figures

Figure 1
Figure 1
Flow diagram of patient progress through study procedures.

References

    1. Urowitz MB, Gladman DD, Tom BD, Ibanez D, Farewell VT. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008;35:2152–8.
    1. Food and Drug Administration. Guidance for industry patient‐reported outcome measures: use in medical product development to support labeling claims. 2010. URL: .
    1. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV. Outcome measures in rheumatology. Lupus 2000;9:322–7.
    1. McElhone K, Abbott J, Teh LS. A review of health related quality of life in systemic lupus erythematosus. Lupus 2006;15:633–43.
    1. McElhone K, Castelino M, Abbott J, Bruce I, Ahmad Y, Shelmerdine J, et al. The LupusQoL and association with demographic and clinical measurements in patients with systemic lupus erythematosus. J Rheumatol 2010;37:2273–9.
    1. Abbott J. Health‐related quality of life measurement in cystic fibrosis: advances and limitations. Chron Respir Dis 2009;6:31–41.
    1. Abbott J, Hart A, Havermans T, Matossian A, Goldbeck L, Barreto C, et al. Measuring health‐related quality of life in clinical trials in cystic fibrosis. J Cyst Fibros 2011;10:S82–5.
    1. McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, et al. Development and validation of a disease‐specific health‐related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. Arthritis Rheum 2007;57:972–9.
    1. McElhone K, Abbott J, Gray J, Williams A, Teh LS. Patient perspective of systemic lupus erythematosus in relation to health‐related quality of life concepts: a qualitative study. Lupus 2010;19:1640–7.
    1. Beaton DE, Bombardier C, Katz JN, Wright JG. A taxonomy for responsiveness. J Clin Epidemiol 2001;54:1204–17.
    1. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002;77:371–83.
    1. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease‐specific quality of life questionnaire. J Clin Epidemiol 1994;47:81–7.
    1. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
    1. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
    1. Yee CS, Farewell V, Isenberg DA, Griffiths B, Teh LS, Bruce IN, et al. The BILAG‐2004 Index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford) 2009;48:691–5.
    1. Yee CS, Cresswell L, Farewell V, Rahman A, Teh LS, Griffiths B, et al. Numerical scoring for the BILAG‐2004 index. Rheumatology (Oxford) 2010;49:1665–9.
    1. Isenberg DA, Allen E, Farewell V, D'Cruz D, Alarcón GS, Aranow C, et al. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis 2011;70:54–9.
    1. The UK Census . 2001. URL: .
    1. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809–13.
    1. Ware JE Jr, Sherbourne CD. The MOS 36‐Item Short‐Form Health Survey I: conceptual framework and item selection. Med Care 1992;30:473–83.
    1. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al. A phase III, randomized, placebo‐controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918–30.
    1. Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double‐blind, placebo‐controlled, multicentre study. Ann Rheum Dis 2014;73:183–90.
    1. StataCorp. StataCorp LP statistical software: release 13. College Station (TX): StataCorp; 2013.
    1. Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability, volume 1: statistics. Berkeley (CA): University of California Press; 1967. pp. 221–33.
    1. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health‐related quality of life. J Clin Epidemiol 2003;56:395–407.
    1. King MT. A point of minimal important difference (MID): a critique of terminology and methods. Expert Rev Pharmacoecon Outcomes Res 2011;11:171–84.
    1. Cella D, Bullinger M, Scott C, Barofsky I. Group vs individual approaches to understanding the clinical significance of differences or changes in quality of life. Mayo Clin Proc 2002;77:384–92.
    1. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient‐reported outcomes. J Clin Epidemiol 2008;61:102–9.
    1. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health‐related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582–92.
    1. Herrmann D. Reporting current, past and changed health status: what we know about distortion. Med Care 1995;33:AS89–94.
    1. Schwartz CE, Sprangers MA. Methodological approaches for assessing response shift in longitudinal health‐related quality‐of‐life research. Soc Sci Med 1999;48:1531–48.
    1. Touma Z, Gladman DD, Ibañez D, Urowitz MB. Is there an advantage over SF‐36 with a quality of life measure that is specific to systemic lupus erythematosus? J Rheumatol 2011;38:1898–905.
    1. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288–91.
    1. Touma Z, Urowitz MB, Gladman DD. SLEDAI‐2K for a 30‐day window. Lupus 2010;19:49–51.
    1. Devilliers H, Amoura Z, Besancenot JF, Bonnotte B, Pasquali JL, Wahl D, et al. Responsiveness of the 36‐item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE. Rheumatology (Oxford) 2015;54:940–9.
    1. Karlson EW, Daltroy LH, Rivest C, Ramsey‐Goldman R, Wright EA, Partridge AJ, et al. Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies. Lupus 2003;12:280–6.
    1. Devilliers H, Guillemin F, Besancenot JF, Pasquali JL, Bonnotte B, Kaminsky P, et al. Validation transculturelle en langue francaise du systemic lupus activity questionnaire [abstract]. Rev Med Interne 2009;30:S376.
    1. Abbott J, Holt A, Hart A, Morton AM, MacDougall L, Pogson M, et al. What defines a pulmonary exacerbation? Perceptions of adults with cystic fibrosis. J Cyst Fibros 2009;8:356–9.
    1. Strand V, Crawford B. Improvement in health‐related quality of life in patients with systemic lupus erythematosus following sustained reductions in anti‐dsDNA antibodies. Expert Rev Pharmacoecon Outcomes Res 2005;5:317–26.
    1. Castelino M, Abbott J, McElhone K, Teh LS. Comparison of the psychometric properties of health‐related quality of life measures used in adults with systemic lupus erythematosus: a review of the literature. Rheumatology (Oxford) 2013;52:684–96.
    1. Meacock R, Harrison M, McElhone K, Abbott J, Haque S, Bruce I, et al. Mapping the disease‐specific LupusQoL to the SF‐6D. Qual Life Res 2015;24:1749–58.
    1. LupusQoL. URL: .

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren